You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》高盛首予海吉亞醫療(06078.HK)「中性」評級 目標價57元
高盛發表報告,首予海吉亞醫療(06078.HK)「中性」投資評級,目標價57元,為42倍市盈率及1.6倍市盈增長率,後者為醫療服務商市場平均水平。 高盛表示,相信海吉亞繼續作為公共醫療系統的補充,透過擴大服務網絡滿足腫瘤學相關醫護需求。該行料2024年前公司將新啟用6間自建醫院,運作病床數目將為去年初3倍,且每病床生產收益大致持平。短期而言,預計海吉亞上半年收入及盈利分別按年增長44%及15%,主要來自去年中收購2間醫院及新開醫院帶來的增長,並部分抵銷新冠防疫影響。全年盈利增長則料為36%。 該行又指,海吉亞自開始放射設備運作以來,已在內地多個省份興建及管理12間腫瘤學醫院。單計去年,其集中於放射治療及相關護理的醫院業務,佔總收入93%,其餘7%收入來自第三方放射治療業務。該行預計公司2021年至2025年收入及盈利年複合增長率分別為29%及27%,主要由病床數量增長推動。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account